News
Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 17, 2023
Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes NEW YORK, Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell...
-
Nov 14, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended...
-
Nov 7, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call on Tuesday, November...
-
Oct 24, 2023
- Resource consumption will be reduced by 50% to accelerate ALS development - Plans underway for registrational Phase 3b U.S. clinical trial for NurOwn in ALS NEW YORK, Oct. 24, 2023 /PRNewswire/...
-
Oct 18, 2023
- Path forward for ALS is a registrational Phase 3b U.S. clinical trial - - Biologics License Application to be withdrawn without prejudice - - Conference call and webcast at 8:30am ET today - NEW...
Tools
Investors
- Overview
- News
- Events & Presentations
- Stock Information
- Financial Reports & Filings
- Corporate Governance